United States News All stories

Neonode (NASDAQ:NEON) reported first-quarter revenue from continuing operations of $0.6 million, a 19.7% increase compared to the same period in 2025.

FedEx (NYSE:FDX) announced that it will execute the separation of its freight business through a tax-free, pro rata dividend of 80.1% of the outstanding shares of the newly formed FedEx Freight Holding Company.

Compass Pathways (NASDAQ:CMPS) reported first-quarter net income of $91.2 million, or $0.71 per basic share, a dramatic reversal from the $17.9 million loss recorded in the same period last year.

DarioHealth (NASDAQ:DRIO) posted first-quarter revenue of $5.6 million, a 6.7% increase from the fourth quarter of 2025.

Nebius Group (NASDAQ:NBIS) reported a first-quarter profit of $621.2 million, or $2.11 per share.

CTW (NASDAQ:CTW) announced Wednesday that revenue for the six months ending January 31, 2026, reached $40.9 million, a 1% decline from the $41.2 million reported in the prior-year period.

Costamare Bulkers (NYSE:CMDB) reported first-quarter net income of $9.9 million, or $0.41 per share.

Valens Semiconductor (NYSE:VLN) posted first-quarter revenue of $16.9 million, edging past its guidance range of $16.3 million to $16.7 million.

Pfizer (NYSE:PFE) announced Wednesday that European regulators have cleared Hympavzi for adolescents and adults with hemophilia A or B with inhibitors, marking a significant expansion for the non-factor therapy in the 27 EU member states, Iceland, Liechtenstein, and Norway.

Arbutus Biopharma (NASDAQ:ABUS), a clinical-stage biopharmaceutical company focused on infectious diseases, reported its financial results for the first quarter ended March 31, 2026.

BrainsWay (NASDAQ:BWAY) delivered a powerful first-quarter 2026 performance, marked by a 35% year-over-year revenue increase to $15.5 million.

Altimmune (NASDAQ:ALT), a clinical-stage biopharmaceutical company developing treatments for metabolic and liver diseases, reported its first-quarter 2026 financial results and provided a business update.

Nexxen International (NASDAQ:NEXN), a global advertising technology platform, reported record-breaking financial results for the first quarter of 2026.

Kornit Digital (NASDAQ:KRNT), a leading provider of digital textile printing technology, announced its first-quarter 2026 financial results.

Caesarstone (NASDAQ:CSTE) reported first-quarter 2026 results that highlighted the early fruits of its structural reorganization.

Beasley Broadcast Group (NASDAQ:BBGI) reported a complex first quarter for 2026, where a return to statutory profitability was accompanied by persistent headwinds in traditional agency advertising.

Similarweb (NYSE:SMWB) reported a significant improvement in its financial health for the first quarter of 2026, swinging to a non-GAAP operating profit as the company scales its footprint among high-value enterprise clients.

Dominari Holdings (NASDAQ:DOMH) revealed a massive acceleration in its business for the first quarter of 2026, fueled by a resurgence in investment banking and underwriting activity.

Riskified (NYSE:RSKD) reported first-quarter 2026 financial results that showcased resilient demand for its AI-driven fraud management platform.

Eos Energy Enterprises (NASDAQ:EOSE) kicked off fiscal year 2026 with an aggressive acceleration in manufacturing output and a transformative strategic partnership.

Dynatrace (NYSE:DT) announced record financial results for its fourth quarter and full fiscal year 2026, officially surpassing the $2 billion mark in annual recurring revenue (ARR).

Voyager Therapeutics (NASDAQ:VYGR) achieved a critical regulatory milestone this week, presenting positive three-month toxicology data for its lead Alzheimer’s disease candidate, VY1706.

Global-e Online (NASDAQ:GLBE) reported a pivotal shift in its financial performance for the first quarter of 2026, swinging to a GAAP net profit as its cross-border e-commerce platform captured a record volume of international trade.

Zenas BioPharma (NASDAQ:ZBIO) announced that it is on track to transition into a commercial-stage company, with plans to submit its first Biologics License Application (BLA) to the U.S. Food and Drug Administration this quarter.